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Objectives. The goals of this study were to examine the safety
and feasibility of a routine (primary) stent strategy in acute
myocardial infarction (AMI).
Background. Limitations of reperfusion by primary percutane-
ous transluminal coronary angioplasty (PTCA) in AMI include
in-hospital recurrent ischemia or reinfarction in 10% to 15% of
patients, restenosis in 37% to 49% and late infarct-related artery
reocclusion in 9% to 14%. By lowering the residual stenosis and
sealing dissection planes created by PTCA, primary stenting may
further improve short- and long-term outcomes after mechanical
reperfusion.
Methods. Three hundred twelve consecutive patients treated
with primary PTCA for AMI at nine international centers were
prospectively enrolled. After PTCA, stenting was attempted in all
eligible lesions (vessel size 3.0 to 4.0 mm; lesion length <22 stents;
and the absence of giant thrombus burden after PTCA, major side
branch jeopardy or excessive proximal tortuosity or calcification).
Patients with stents were treated with aspirin, ticlopidine and a
60-h tapering heparin regimen.
Results. Stenting was attempted in 240 (77%) of 312 patients,
successfully in 236 (98%), with Thrombolysis in Myocardial
Infarction grade 3 flow restored in 230 patients (96%). Patients
with stents had low rates of in-hospital death (0.8%), reinfarction
(1.7%), recurrent ischemia (3.8%) and predischarge target vessel
revascularization for ischemia (1.3%). At 30-day follow-up, no
additional deaths or reinfarctions occurred among patients with
stents, and target vessel revascularization was required in only
one additional patient (0.4%).
Conclusions. Primary stenting is safe and feasible in the majority
of patients with AMI and results in excellent short-term outcomes.
(J Am Coll Cardiol 1998;31:23–30)
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Prospective, randomized trials comparing thrombolytic ther-
apy with primary percutaneous transluminal coronary angio-
plasty (PTCA) in patients with an acute myocardial infarction
(AMI) have documented superior reperfusion rates and im-
proved clinical outcomes with the invasive approach (1–5).
However, several limitations of primary PTCA remain to be
overcome. After successful PTCA, recurrent ischemia still
occurs in 10% to 15% of patients (1–6), which results in
hemodynamic and arrhythmic complications, necessitates re-
peat catheterization and revascularization procedures, pro-
longs the hospital stay and increases costs (6). Reinfarction
develops in 3% to 5% of patients before hospital discharge,
and infarct-related artery (IRA) reocclusion in 5% to 10% of
vessels, which results in blunted myocardial recovery and
excess mortality (1–17). Finally, angiographic restenosis has
been documented in 37% to 49% of patients after primary
PTCA, with late infarct-related vessel reocclusion in 9% to
14% (9,18–21). As a result, ;20% of patients require repeat
PTCA or bypass surgery within 6 months after discharge
(1–4,20).
Compared with PTCA, the implantation of coronary stents
in the elective setting has been shown to reduce angiographic
restenosis and improve late clinical outcomes (22–24). How-
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ever, stenting has historically been contraindicated in
thrombus-containing lesions because of the risk of subacute
thrombosis (25,26). With advances in stent implantation tech-
nique derived from intravascular ultrasound imaging (27,28),
and the recognition of the importance of adequate platelet
inhibition (29–31), the incidence of subacute thrombosis has
progressively fallen despite stenting in increasingly complex
subsets, including acute ischemic syndromes and thrombus-
laden lesions (32,33). We therefore hypothesized that a routine
(primary) stent strategy would be feasible in the majority of
patients with AMI and would result in low rates of recurrent
ischemia, reinfarction and late restenosis.
Methods
Patients and clinical centers. To test the feasibility, safety
and efficacy of a primary stent strategy in AMI, nine centers
experienced in both stenting and primary PTCA (seven in
North America, one in South America and one in Europe)
were invited to participate in a large pilot experience. Patient
entry criteria were deliberately chosen to be nonrestrictive.
Thus, consecutive patients of any age with chest pain #12 h in
duration, with any electrocardiographic (ECG) pattern of AMI
were enrolled. Patients with previous bypass surgery and vein
graft occlusion were included. Patients were excluded only for
the presence of cardiogenic shock (systolic blood pressure
,80 mm Hg for .30 min not responsive to fluids) and for
absolute contraindications to heparin, aspirin or ticlopidine,
including hemorrhagic diathesis, known allergy or thrombocy-
topenia. Patients were also excluded if they had previously
received thrombolytic therapy during the same hospital period
or were participating in other investigational studies. The
protocol was approved by the investigational review board at
each clinical site, and written informed consent was obtained
from all patients before enrollment.
Study protocol. Patients were treated in the emergency
room with 324 mg of chewable aspirin (500 mg of intravenous
aspirin in France), 250 to 500 mg of oral ticlopidine and a
5,000- to 10,000-U bolus of intravenous heparin. Intravenous
beta-blockade was administered in the absence of contraindi-
cations. Patients were then transferred emergently to the
cardiac catheterization laboratory and underwent left ventricu-
lography and coronary arteriography. Low osmolar, ionic
contrast medium (Ioxaglate) was used to minimize the risk of
thromboembolic complications (34,35). PTCA was then per-
formed if appropriate. As previously described (1), PTCA was
deferred for medical therapy if Thrombolysis in Myocardial
Infarction (TIMI) grade 3 flow was present with an IRA
stenosis ,70%, if a very small vessel was occluded or if the
IRA could not be identified. PTCA was deferred for urgent or
emergent bypass surgery if TIMI grade 3 flow was present in
the infarct-related vessel, with either a left main stenosis
.60%, severe triple-vessel disease or other lesion characteris-
tics unfavorable for PTCA (1). All patients in whom primary
PTCA was performed were formally entered into the study,
and patients treated medically or surgically were excluded.
Before PTCA, additional heparin was given to achieve an
activated clotting time of .350 s. PTCA was then performed
using standard over the wire balloons and floppy guidewires as
previously described (1) to restore patency and anterograde
flow. After restoration of flow, the lesion was assessed for stent
eligibility. Stent implantation was then attempted in all eligible
lesions. The Johnson & Johnson Palmaz-Schatz stent was
considered the stent of choice, given its proven ability to
reduce restenosis in randomized trials (22–24). The sheath
delivery system was used in all centers except in France, where
stents were hand crimped onto high pressure balloons. For this
pilot experience, stenting was deferred if the lesion would
require three or more Palmaz-Schatz stents for coverage; if the
reference segment was visually ,3.0 mm or .4.0 mm in
diameter such that 3.0- to 4.0-mm stents could not be used; if
the infarct-related lesion was a true ostial left anterior de-
scending or left circumflex coronary artery lesion; if a major
side branch would be placed in jeopardy ($3.0-mm diameter);
or if excessive proximal tortuosity or lesion calcification was
present, making it unlikely that the stent could be successfully
delivered or fully expanded. No lesion was excluded because of
the presence of thrombus before PTCA. However, if a large
thrombus burden was present after PTCA refractory to repeat
dilation or pharmacologic treatment (thrombus more than
twice the vessel diameter), stenting was also deferred. How-
ever, stenting was routinely performed directly into small or
moderate amounts of thrombus. Additional reasons for not
stenting individual lesions were left to the discretion of the
operator and were recorded.
After stent implantation, noncompliant balloons (balloon/
artery ratio of 1 to 1.1:1) were used to fully deploy the stent or
stents at high pressure (18 atm recommended). By protocol,
any persistent dissection was treated with additional stents. An
angiographic filling defect consistent with thrombus after
stenting was treated with additional PTCA and, if still refrac-
tory, with intracoronary thrombolysis, intravenous abciximab
or, conservatively, at the operator’s discretion. All lesions with
a stenosis $70% either proximal or distal to the infarct-related
lesion that might represent a significant inflow or outflow
obstruction were also stented.
After the procedure, sheaths were removed when the ACT
fell below 170 s. Six hours later, a heparin drip was restarted
Abbreviations and Acronyms
ACT 5 activated clotting time
AMI 5 acute myocardial infarction
CK-MB 5 creatine kinase-MB fraction
ECG 5 electrocardiogram, electrocardiographic
IRA 5 infarct-related artery
PAMI 5 Primary Angioplasty in Myocardial
Infarction (trial)
PTCA 5 percutaneous transluminal coronary
angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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with a 2,500-U intravenous bolus and was adjusted to maintain
the activated partial thromboplastin time at 60 to 85 s for 48 h,
then reduced to half dose for 12 h to avoid a rebound
hypercoagulable state (36), after which it was discontinued. All
patients were treated with oral aspirin (325 mg/day), ticlopi-
dine (250 mg twice daily), beta-adrenergic blocking agents and
angiotensin-converting enzyme inhibitors if hypertension,
heart failure or reduced left ventricular function was present.
Initially, warfarin sodium (Coumadin) was recommended if an
unfavorable stent result was obtained (.10% residual stenosis
or a persistent filling defect or unstented dissection). However,
shortly after enrollment commenced, with the demonstration
by Schomig et al. (30) that adverse event rates after high risk
stenting were lower with an aspirin and ticlopidine regimen
than an aspirin and warfarin regimen, warfarin was no longer
permitted (except for nonstent indications, such as valve
prosthesis and atrial fibrillation). No patient received warfarin
for stent anticoagulation.
Patients were progressively ambulated and discharged when
stable, as in the Primary Angioplasty in Myocardial Infarction
(PAMI) 2 study (12,13). Thus, stable low risk patients were
generally discharged on hospital day 3 to 4, and stable high risk
patients were discharged on day 5 to 7. After discharge,
follow-up visits were performed at 1 and 6 months. Aspirin was
continued indefinitely, and ticlopidine was maintained for 4
weeks and then discontinued. Complete blood counts were
checked at 2 and 4 weeks after discharge. Other medications
were used as clinically indicated.
Definitions. Anterograde flow was assessed by TIMI flow
grade (37). TIMI grade 3 flow was defined by the core angio-
graphic laboratory as complete opacification of the distal
coronary bed by the third cardiac cycle. IRA reocclusion was
present when follow-up angiography of a previously patent
vessel demonstrated $90% stenosis and TIMI grade 0 to 1
flow. Recurrent ischemia was defined as recurrent symptoms
consistent with angina plus new ECG changes, new sustained
hypotension or pulmonary edema, a new loud systolic murmur,
creatine kinase-MB fraction (CK-MB) reelevation or the need
for IRA revascularization with either repeat PTCA or stenting
or bypass surgery. Reinfarction was defined as recurrent isch-
emic symptoms or ECG changes, with any CK-MB reelevation.
Congestive heart failure was defined as Killip class III to IV and
sustained hypotension as systolic blood pressure ,90 mm Hg
for .30 min, unresponsive to fluids or pressor dependent.
Data collection and statistical analysis. Detailed in-
hospital and 1-month follow-up case report forms were pro-
spectively completed for each patient and were confirmed at
the data coordinating center by separate review of catheteriza-
tion reports, ECGs, laboratory tests and discharge summaries.
Adverse events were reported to the clinical coordinating
center within 24 h of occurrence. Quantitative coronary anal-
ysis was performed by an independent core angiographic
laboratory at the Washington Hospital Center using previously
validated methodology (38). Of 312 index films, 300 (96%)
were technically able to be analyzed; the remainder were
recorded on a CD-ROM format that presented an incompat-
ible synchronization signal and could not be acquired. Data
were entered into a computerized database, and statistical
analysis was performed with a commercially available package
(Statview 4.5, Abacus Concepts).
By intention to treat analysis, unless otherwise stated, the
“stent” group comprised all patients in whom stenting was
attempted, even if the stent was not ultimately implanted.
Categoric variables were compared with chi-square or Fisher
exact tests, whereas continuous variables were compared with
the unpaired Student t test. A p value ,0.05 was required for
statistical significance.
Results
Enrollment and stent eligibility. Between June 1995 and
July 1996, primary PTCA was performed in 312 consecutive
patients with an AMI meeting the enrollment criteria at nine
clinical centers. After initial PTCA, stenting was attempted in
240 patients (77%). In 72 patients, stenting was not considered
feasible; these patients were treated by primary PTCA alone.
The baseline demographic, admission and angiographic fea-
tures of patients in whom stenting was or was not attempted
appear in Tables 1 and 2. The major reasons given by the
investigators for not attempting to stent are shown in Table 3.
Compared with lesions in which stenting was attempted,
lesions in which stenting was not attempted were located more
distally in the coronary tree and had smaller reference segment
diameters. Stenting was performed more frequently in patients
with single-vessel disease, and PTCA only was more common
in patients with triple-vessel disease.
Table 1. Baseline Clinical and Angiographic Features in
312 Patients
Stent
(n 5 240)
PTCA Only
(n 5 72)
p
Value
Age (yr) 61 6 12 61 6 11 0.90
Women 61 (25.4%) 22 (30.6%) 0.39
Hypertension 107 (44.6%) 32 (44.4%) 0.97
Diabetes mellitus 37 (15.4%) 11 (15.3%) 0.98
Current cigarette smoking 96 (40.0%) 30 (41.7%) 0.80
Prior MI 31 (12.9%) 11 (15.3%) 0.61
Prior PTCA 24 (10.0%) 8 (11.1%) 0.79
Prior CABG 15 (6.3%) 4 (5.6%) 0.83
Prior stroke or TIA 17 (7.1%) 6 (8.3%) 0.72
ECG infarct location
Anterior 88 (36.7%) 20 (27.8%) 0.15
Inferior 126 (52.5%) 44 (61.1%) 0.22
Posterior 7 (2.9%) 0 0.59
Lateral 6 (2.5%) 3 (4.2%) 0.70
Subendocardial 13 (5.4%) 5 (6.9%) 0.52
Admission Killip class $II 30 (12.5%) 7 (9.7%) 0.52
Symptom onset to ER
arrival (min)
174 6 190 169 6 157 0.84
Data presented are mean value 6 SD or number (%) of patients. CABG 5
coronary artery bypass graft surgery; ECG 5 electrocardiographic; ER 5
emergency room; MI 5 myocardial infarction; PTCA 5 percutaneous translu-
minal coronary angioplasty; TIA 5 transient ischemic attack.
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Stent deployment. Stents were successfully delivered to the
lesion and deployed in 236 (98%) of 240 patients. In four
patients, the Palmaz-Schatz stent with sheath delivery system
would not reach or cross the lesion, and the stent was
successfully withdrawn without being lost. Among stent group
patients, a mean (6SD) of 1.4 6 0.7 stents (range 1 to 7) were
implanted per patient (97% JJIS, 1% Cook, 1% Schneider, 1%
AVE). The mean stent size was 3.4 6 0.5 mm (median 3.5),
and 17.3 6 2.4 atm of pressure was used for postimplantation
stent expansion. By quantitative coronary analysis, the final
measured mean balloon/artery ratio was 1.08 6 0.14. Intravas-
cular ultrasound guidance was used in 48 stent group patients
(20%) and in 3 with PTCA only (4%). Adjunctive antiplatelet
and thrombolytic drug use in the catheterization laboratory
was infrequent; intravenous abciximab was given to 21 patients
(6.7%) (including 13 stent group patients [5.4%] and 8 with
PTCA only [11.1%]), and intracoronary urokinase was used in
only 4 patients (1.3%) (3 stent group patients [1.2%] and 1
with PTCA only [1.4%]).
Core laboratory angiographic analysis appears in Figure 1.
The comparison of the site and core laboratory angiographic
assessment is shown in Table 4. By core laboratory analysis,
TIMI grade 3 flow was present at the end of the procedure in
92.7% of patients (94.4% of stent group patients vs. 87.3% of
patients with PTCA only, p 5 0.04). The mean postprocedural
residual stenosis was 12.1% 6 16.2% in the stent group versus
33.3% 6 14.3% in the PTCA-only group (p , 0.0001) (Fig. 1).
Thus, a ,50% residual stenosis with TIMI grade 3 flow was
obtained in 93.7% of the stent group versus 77.3% of the
PTCA-only group (p , 0.0001).
Clinical outcomes. Major in-hospital adverse outcomes are
presented in Table 5. Repeat predischarge catheterization
(which was not required by the protocol) was performed in
18% of patients, usually for physician preference or recurrent
atypical chest pain without ECG changes (Table 6). Among
stent group patients, stent occlusion was documented in two
(0.8%). In two additional patients with reinfarction, recath-
eterization revealed moderate stenoses with peristent dissec-
tion in one and in-stent thrombus in the other. One additional
stent group patient who did not undergo repeat catheterization
had a major reinfarction on day 7, presumably due to stent
thrombosis.
The mean hospital stay was 6.2 6 3.7 days among stent
group patients versus 7.1 6 6.4 days in patients undergoing
PTCA only (p 5 0.11). Among stent group patients, 98% were
discharged with aspirin or ticlopidine (with lovenox in 1%), or
both, and 2% were discharged with warfarin with or without
aspirin. One-month follow-up data were complete for 309
(99.7%) of 310 discharged patients. Adverse events occurring
within the first 30 days after discharge were infrequent among
stent group patients and appear in Table 7.
Discussion
The present study demonstrates that a primary stent strat-
egy is safe and feasible in the majority of patients with an AMI
undergoing mechanical reperfusion. With the routine use of
high pressure implantation techniques and a post-stent antico-
agulation regimen of aspirin, ticlopidine and a 60-h heparin
taper, reinfarction occurred in only four stent group patients
Table 2. Angiographic Characteristics of Patients in Whom Stenting
Was or Was Not Attempted
Stent
(n 5 240)
PTCA Only
(n 5 72)
p
Value
LVEF (%) 48 6 13 51 6 11 0.08
No. of diseased epicardial
vessels
One 119 (49.6%) 27 (37.5%) 0.009
Two 70 (29.2%) 22 (30.6%) 0.82
Three 51 (21.2%) 23 (31.9%) 0.01
Infarct-related vessel type
Native coronary artery 231 (96.2%) 68 (94.4%) 0.50
Saphenous vein bypass graft 7 (2.9%) 4 (5.6%) 0.29
Internal mammary artery graft 2 (0.8%) 0 0.99
Infarct-related artery distribution
LMCA 1 (0.4%) 0 0.99
LAD 88 (36.7%) 24 (33.3%) 0.61
LCx 38 (15.8%) 15 (20.8%) 0.32
RCA 113 (47.1%) 33 (45.9%) 0.85
Infarct-related lesion location
Proximal vessel 125 (52.1%) 31 (43.1%) 0.18
Mid vessel 93 (38.8%) 17 (23.6%) 0.01
Distal vessel or branch 22 (9.1%) 24 (33.3%) , 0.0001
Ref segment diam (mm)* 3.17 6 0.53 2.80 6 0.71 , 0.0001
Lesion MLD (mm)* 0.28 6 0.46 0.38 6 0.62 0.14
Lesion DS (%)* 90.7 6 15.1 87.0 618.4 0.09
*Core laboratory analysis (n 5 300). Data presented are mean value 6 SD
or number (%) of patients. diam 5 diameter; DS 5 diameter stenosis; LAD 5
left anterior descending coronary artery; LCx 5 left circumflex coronary artery;
LMCA 5 left main coronary artery; LVEF 5 left ventricular ejection fraction;
MLD 5 minimal lumen diameter; PTCA 5 percutaneous transluminal coronary
angioplasty; RCA 5 right coronary artery; Ref 5 reference.
Table 3. Operator Reasons for Not Stenting 72 Lesions*
Vessel too small for $3.0-mm diam stent 30 (9.6%)
Lesion length $3 stents 8 (2.6%)
Excessive proximal tortuosity 7 (2.2%)
Major side branch jeopardy 6 (1.9%)
Large thrombus burden 5 (1.6%)
Poor distal runoff (diffuse disease) 4 (1.3%)
Vessel diam .4.0 mm 2 (0.6%)
Unresolved no reflow after PTCA 2 (0.6%)
Predischarge elective CABG planned 2 (0.6%)
Heavy calcification 2 (0.6%)
Bleeding diathesis 2 (0.6%)
Diffuse ectasia 2 (0.6%)
Additional reasons
Ostial LAD 1 (0.3%)
VSD identified 1 (0.3%)
Accordian RCA 1 (0.3%)
Unsure of culprit lesion 1 (0.3%)
*More than one reason was present in some patients. Data presented are
number (%) of patients. VSD 5 ventricular septal defect; other abbreviations as
in Tables 1 and 2.
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(1.7%), despite the known presence of thrombus in most
patients with AMI (39,40). Furthermore, recurrent ischemia
occurred in only 3.8% of stent group patients, strikingly less
common than the 10% to 15% incidence observed after
primary PTCA in our previous PAMI trials (1,2,6,12,13). The
low observed rates of subacute thrombosis and 30-day target
vessel revascularization are also encouraging. Thus, a strategy
of stenting all eligible lesions (achievable in 77% of patients)
would appear to result in at least equivalent and possibly
superior short-term outcomes than balloon dilation alone
(1–6,12,13).
Rationale for the safety of stenting in AMI. The predom-
inant mechanism of coronary occlusion in AMI is thrombotic
closure of a ruptured atherosclerotic plaque (39,40), and thus
concern has appropriately been expressed that stenting during
the acute phase of myocardial infarction may increase the risk
of stent thrombosis. In contrast, occlusive stent thrombosis
occurred in only three (1.3%) patients with AMI in the present
study. Several possible explanations may underlie the apparent
safety of stenting in an obviously thrombotic environment.
After primary PTCA for AMI, the presence of dissection and
a residual stenosis .30% have been shown to be major
predictors of recurrent ischemia and IRA reocclusion (41–43),
both limitations of balloon dilation that are routinely overcome
by stenting. Reinfarction after primary stenting may therefore
be less common than after primary PTCA (as this study
suggests), even if subacute thrombosis does rarely occur.
Furthermore, the establishment by the stent of a wide lumen
channel with brisk anterograde flow and no dissection planes
may facilitate natural clot resolution by endogenous fibrinoly-
sis (with aspirin, ticlopidine and heparin inhibiting new throm-
bus formation). Although it is possible that vessel occlusion
after stenting in AMI may be asymptomatic and therefore
undetected without routine repeat catheterization, TIMI grade
3 flow was present in all 39 patients without recurrent ischemia
who underwent predischarge angiography, suggesting that
silent stent occlusion occurs infrequently. Late patency of the
infarct-related vessel will be assessed with protocol angiogra-
phy during the 6-month follow-up phase of this study.
Technical issues. Stenting is technically more demanding
than PTCA, and meticulous attention to detail is mandatory to
reproduce these results. Stents must not be underdeployed or
incompletely opposed to the vessel wall; because the vessel
“grows” with improving anterograde flow, stent expansion may
need to be increased with larger balloons to ensure a stent/
artery ratio .1:1. The routine use of high pressure is recom-
mended to ensure vessel wall apposition of the stent and
adequate expansion, which may reduce subacute thrombosis
Figure 1. Minimal lumen diameter (left) and percent
diameter stenosis (right) before and after interven-
tion, expressed as a cumulative distribution function.
Solid circles 5 patients in whom stenting was at-
tempted; open squares 5 patients treated with PTCA
only.
Table 4. Site and Core Laboratory Angiographic Measures
Site Assessment Core Laboratory Assessment
Stent
(n 5 240)
PTCA
(n 5 72)
Total
(n 5 312)
Stent
(n 5 231)
PTCA
(n 5 69)
Total
(n 5 300)
TIMI flow grade
Initial
0/1 79% 79% 79% 72% 64% 70%
2 14% 10% 13% 11% 10% 11%
3 7% 11% 8% 17% 26% 19%
Final
0/1 1% 4% 2% 2% 3% 2%
2 3% 1% 2% 4% 10% 5%
3 96% 95% 96% 94% 87% 93%
Initial MLD (mm) — — — 0.28 6 0.46 0.38 6 0.62 0.30 6 0.50
Final MLD (mm) — — — 2.77 6 0.59 1.86 6 0.61 2.56 6 0.70
Initial %DS 99 6 4 98 6 5 99 6 5 91 6 15 87 6 18 90 6 16
Final %DS 3 6 11 24 6 17 8 6 16 12 6 16 33 6 14 17 6 18
Data presented are mean value 6 SD or percent of patients. TIMI 5 Thrombolysis in Myocardial Infarction; other
abbreviations as in Table 2.
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(27,28). Eighteen atmospheres was chosen for the present
study because the Palmaz-Schatz stent continues to expand as
implantation pressure is increased from 12 to 18 atm (44). The
use of low osmolar ionic contrast medium (Ioxaglate) is
strongly recommended to reduce thromboembolic complica-
tions while at the same time producing minimal hemodynamic
disturbance (34,35). Ticlopidine (in addition to aspirin) is
mandatory (29–31) and may be given as a loading regimen of
500 mg twice daily for 48 h, which achieves significant anti-
platelet activity more rapidly than standard dosing (45). War-
farin should be avoided because of its lack of efficacy, in-
creased vascular and hemorrhagic complications and the
possible induction of a prothrombotic state from protein C and
S inhibition (22,23,29–31,46). With these guidelines, recurrent
ischemia and reinfarction after stenting in AMI occurred
rarely despite the infrequent use of intravenous abciximab and
intracoronary thrombolytic therapy.
Nonetheless, despite the expertise of the operators partic-
ipating in this study, several stent-related complications oc-
curred, some of which may be preventable with increasing
operator experience. Of note, one patient required emergency
bypass surgery after a major stent-induced dissection, whereas
additional unplanned stents were required in seven patients
(3%) to treat peristent dissection not present after PTCA. The
importance of scaffolding all margin dissections is also evi-
denced by the fact that two patients developed recurrent
ischemia related to peristent edge tears that were left un-
stented (against protocol), only to resurface as an extensive
propagating dissection 1 to 3 days after the initial procedure.
Two patients also had partial stent thrombosis related to
underdeployment (one stent undersized, one stent implanted
at low pressure), both successfully treated with repeat PTCA
and more optimal stent expansion. With improved operator
technique, new stent designs soon to be available (including
stents coated with thromboresistant materials such as heparin
and phosphorylcholine [47–49]), and the possible adjunctive
use of parenteral, local or stent-bonded glycoprotein IIb/IIIa
inhibitors (50,51), the safety profile of stenting in AMI may be
further enhanced.
Limitations of the study. Although the present prospec-
tive, multicenter trial is the largest series to date of primary
stenting in AMI, all the caveats of comparing data from a
registry series to historical control subjects apply, including the
possibility of selection bias. Specifically, the outcomes of the
23% of patients in the present study in whom PTCA only was
performed were better than might otherwise have been ex-
pected. Although this most likely reflects the fact that the
PTCA-only group represented a lower risk subset with smaller
vessels and less myocardium at risk than the stent group
(Tables 2 and 3), the possibility of improved outcomes due to
Table 5. Major In-Hospital Adverse Effects in 312 Patients
Stent
(n 5 240)
PTCA Only
(n 5 72)
p
Value
Death 2 (0.8%) 0 0.99
Reinfarction 4 (1.7%) 0 0.58
Recurrent ischemia 9 (3.8%) 2 (2.9%) 0.69
Repeat PTCA 12 (5.0%) 6 (8.3%) 0.29
Of infarct-related vessel 5 (2.1%) 4 (5.6%) 0.13
Of non–infarct-related vessel 9 (3.8%) 2 (2.8%) 0.69
CABG 7 (2.9%) 9 (12.5%) 0.001
Emergent from cath lab 1 (0.4%) 0 0.99
Urgent or emergent from
outside cath lab
3 (1.3%) 4 (5.6%) 0.03
Elective 3 (1.3%) 5 (6.9%) 0.007
Target vessel revasc for ischemia 3 (1.3%) 2 (2.9%) 0.37
Stroke 1 (0.4%) 0 0.99
Hemorrhagic 0 0 0.99
Nonhemorrhagic 1 (0.4%) 0 0.99
New-onset congestive heart failure 10 (4.2%) 3 (4.2%) 0.99
New-onset sustained hypotension 6 (2.5%) 5 (6.9%) 0.07
Blood transfusion 5 (2.1%) 7 (9.7%) 0.003
Groin complication* 6 (2.5%) 0 0.34
Requiring US compression or
surgical repair
3 (1.3%) 0 0.99
*Major hematoma, limb ischemia, arteriovenous fistula or pseudoaneurysm.
Data presented are number (%) of patients. Cath lab 5 catheterization
laboratory; revasc 5 revascularization; US compression 5 ultrasound-guided
compression; other abbreviations as in Table 1.
Table 6. Predischarge Cardiac Catheterization: Indications
and Findings
Stent
(n 5 240)
PTCA Only
(n 5 72)
p
Value
Predischarge recath performed 43 (17.9%) 13 (18.1%) 0.99
Indication
Recurrent ischemia 4 (1.7%) 1 (1.4%) 0.99
Chest pain without ECG
changes
10 (4.2%) 3 (4.2%) 0.99
Recurrent ventricular
arrhythmias
1 (0.4%) 0 0.99
Physician preference 22 (9.2%) 6 (8.3%) 0.83
For staged PTCA of
noninfarct-related vessel
6 (2.5%) 3 (4.2%) 0.44
Status of infarct-related vessel
Stenosis $50% 5 (2.1%) 6 (8.3%) 0.01
Reocclusion 2 (0.8%) 1 (1.4%) 0.54
Data presented are number (%) of patients. recath 5 recatheterization;
other abbreviations as in Table 1.
Table 7. Adverse Events Occurring Within 30 Days After
Hospital Discharge
Stent
(n 5 237)
PTCA Only
(n 5 72)
p
Value
Death 0 0 0.99
Reinfarction 0 1 (1.4%) 0.99
Revasc procedures 8 (3.4%) 9 (12.5%) 0.003
PTCA/atherectomy/stent 7 (3.0%) 6 (8.3%) 0.05
CABG 1 (0.4%) 3 (4.2%) 0.04
Target vessel revasc 1 (0.4%) 5 (6.9%) 0.0004
Ticlopidine side effects* 10 (4.2%) 0 0.07
*Rash (n 5 6), dyspepsia (n 5 2), neutropenia (n 5 1), thrombocytopenia
(n 5 1). Data presented are number (%) of patients. Abbreviations as in Tables
1 and 5.
28 STONE ET AL. JACC Vol. 31, No. 1
PRIMARY STENTING IN ACUTE MYOCARDIAL INFARCTION January 1998:23–30
evolving PTCA technique or selection bias cannot be totally
discounted. Thus, firm conclusions regarding the superiority of
primary stenting in eligible patients over primary PTCA cannot
be made from this study. Furthermore, the favorable results of
stenting during AMI in this report cannot be generalized to
patient and lesion subsets that were excluded, such as small
vessels and diffuse disease. As new, smaller stents for 2.0- to
2.5-mm vessels and longer stents are introduced, their safety
and efficacy profiles in AMI will need to be established. Finally,
because this study was designed to examine the feasibility and
efficacy of a primary stent strategy in patients undergoing
primary PTCA, we did not collect outcomes data for those
patients undergoing angiography in whom PTCA was not
performed, which in the previous PAMI studies has averaged
10% of patients with AMI (1,12,13).
Although the present study suggests that stenting is safe and
feasible in the majority of patients with AMI over the short
term, and results in excellent clinical outcomes, no inferences
from this report can be drawn about late clinical events and
restenosis, nor about the relative cost-effectiveness of a pri-
mary stent strategy relative to PTCA (52). Future studies must
also address possible synergy between platelet glycoprotein
IIb/IIIa receptor blockade and stenting in AMI. Large-scale,
randomized, multicenter trials are thus mandated to establish
the role of a primary stent strategy in patients with AMI.
Nonetheless, given the impressive short-term results of the
present study, if randomized trials demonstrate that stenting
can reduce the high rates of restenosis and adverse clinical
events otherwise present after primary PTCA, stenting has the
potential to be the next major breakthrough in the mechanical
reperfusion therapy of AMI.
Appendix
Participating Institutions and Investigators for the
Primary Angioplasty in Myocardial Infarction Stent
Pilot Trial
Clinical and Data Coordinating Centers. The Cardiovascular Institute, El
Camino Hospital: Gregg W. Stone, JoAnn McDonnell, Nancy Richardson.
William Beaumont Hospital: Cindy L. Grines, William W. O’Neill, Denise Jones.
Clinical Centers. El Camino Hospital, Mountain View, California: Gregg W.
Stone (Principal Investigator), Frederick G. St. Goar, Clayton Bavor, Edward
Bough, Robert Constantino, Martin Klughaupt, Ibrahim Saah, Robert Master,
Robert Ratshin. The Moses H. Cone Memorial Hospital, Greensboro, North
Carolina: Bruce R. Brodie (Principal Investigator), Denise Muncy, Thomas
Stuckey, Richard Weintraub, Thomas Kelly, Jonathan Berry. Virginia Beach
General Hospital, Virginia Beach, Virginia: John J. Griffin (Principal Investigator),
John Kenerson, Sherry Theodosiou. Institut Cardiovasculaire Paris Sud, Antony,
France: Marie Claude Morice (Principal Investigator), Pierre Dumas, Yves
Louvard, Gaetan Karrillon, Thierry Lefevre, Dominique Robert, Mireille Simon.
Hospital Santa Case de Misericordia, Curitiba, Brazil: Costantino Costantini
(Principal Investigator), Sergio Tarbine. St. Mary of the Plains, Lubbock, Texas:
Paul A. Overlie (Principal Investigator), Fawwaz M. Shoukfeh, Marc J. Levine,
Karen E. Moore, Deenie Stone. St. Vincent’s Hospital, Indianapolis, Indiana:
Thomas J. Linnemeier (Principal Investigator), Donald A. Rothbaum, Janice
Coverdale. Lenox Hill Hospital, New York, New York: Jeffrey A. Moses (Principal
Investigator), Antonio Colombo. St. Lukes Hospital, Kansas City, Missouri: Tom
Shimshak (Principal Investigator).
Core Angiographic Laboratory. Cardiology Research Foundation, Washington
Hospital Center, Washington, D.C.: Jeffrey J. Popma (Director), Alexandra
Lansky, Alan J. Merritt.
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